In triple-negative breast cancer, even low-androgen tumors respond to anti-androgen therapy

Clinical trials are underway of anti-androgen drugs against high-androgen triple-negative breast cancers, and new work shows the threshold for benefit from anti-androgen therapies may be much lower than previously thought: even breast cancers with few androgen receptors benefit from anti-androgen therapy.